Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
NEWARK, Calif., Feb. 08, 2017 -- Depomed, Inc. (NASDAQ:DEPO) today announced that members of senior management will participate in fireside chats at the following healthcare conferences during the month of February.
LEERINK Partners 6th Annual Global Healthcare Conference
Date: Wednesday, February 15, 2017
Time: 3:30 p.m. EST
Location: New York, New York
RBC Capital Markets 2017 Global Healthcare Conference
Date: Thursday, February 23, 2017
Time: 8:00 a.m. EST
Location: New York, New York
The fireside chats will be webcast live and may be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of these events will be archived for 30 days on the company's website.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
Investor Contact: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
